LRRK2 and myelofibrosis: To extend the findings beyond birabresib, we also used pelabresib (CPI‐0610), a BET inhibitor currently in phase 3 trial for myelofibrosis (NCT04603495), to validate the synergism with LRRK2‐IN‐1 (Figure S2).